Save Product
Product Details
Synonym
PVR, FLJ25946, PVS, CD155, TAGE4, HVED, NECL5
Source
Biotinylated Human CD155, Fc,Avitag (CD5-H82F6) is expressed from human 293 cells (HEK293). It contains AA Trp 21 - Asn 343 (Accession # NP_006496.2).
Predicted N-terminus: Trp 21
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 63.5 kDa. The protein migrates as 80-106 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human CD155, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) is more than 85% and the molecular weight of this protein is around 155-185 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human TIGIT, Fc Tag (Cat. No. TIT-H5254) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) with a linear range of 8-125 ng/mL (QC tested).
Protocol
Immobilized Human DNAM-1, Fc Tag (Cat. No. DN1-H5257) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) with a linear range of 0.02-0.312 μg/mL (Routinely tested).
Protocol
Serial dilutions of TIGIT antibody antibody (1:2 serial dilutions, from 20 μg/mL to 0.0097 μg/mL) were added into Human TIGIT, His Tag: Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.
Protocol
Bioactivity-FACS
FACS analysis shows that the binding of Biotinylated Human CD155, Fc,Avitag (Cat. No. CD5-H82F6) to 293T overexpressing TIGIT was inhibited by increasing concentration of neutralizing Anti-Human TIGIT MAb. The concentration of CD155 used is 1 μg/mL. The IC50 is 0.201 μg/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
CD155/PVR was originally isolated based on its ability to mediate polio virus attachment to host cells. The fulllength (or CD155 alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20 aa signal sequence, a 323 aa extracellular region, a 24 aa TM segment and a 50 aa cytoplasmic tail. The extracellular region contains one N terminal V type and two C2 type Ig like domains.
CD155 is a transmembrane protein with 3 extracellular immunoglobulin-like domains, D1-D3, where D1 is recognized by the virus. Low resolution structures of CD155 complexed with poliovirus have been obtained using electron microscopy while a high resolution structures of theectodomain D1 and D2 of CD155 were solved by x-ray crystallography.
Recent Advances
Drug Development Progress- English Name：
Poliovirus receptor
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
2 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing